American Journal of Cardiology
Volume 104, Issue 6 , Pages 835-839 , 15 September 2009

Role of Renin-Angiotensin System Blockade in Patients With Diabetes Mellitus

  • Manoela F.B. Braga, MD

      Affiliations

    • Cardiometabolic Risk Initiative, St. Michael's Hospital, University of Toronto, Toronto, Ontario Canada
    • ,
  • Lawrence A. Leiter, MD

      Affiliations

    • Cardiometabolic Risk Initiative, St. Michael's Hospital, University of Toronto, Toronto, Ontario Canada
    • Division of Endocrinology and Metabolism, University of Toronto, Toronto, Ontario, Canada
    • Corresponding Author InformationCorresponding author: Tel: 416-867-7441; fax: 416-867-3696

Received 21 January 2009 ,Revised 5 May 2009 ,Accepted 5 May 2009.

References 

  1. Chaturvedi N. The burden of diabetes and its complications: trends and implications for intervention. Diabetes Res Clin Pract. 2007;76(suppl):S3–S12
  2. American Diabetes Association. Standards of medical care in diabetes—2006. Diabetes Care. 2006;29(suppl):S4–S42
  3. Balkau B, Hu G, Qiao Q, Tuomilehto J, Borch-Johnsen K, Pyörälä K. Prediction of the risk of cardiovascular mortality using a score that includes glucose as a risk factor (The DECODE Study). Diabetologia. 2004;47:2118–2128
  4. Cooper ME. The role of the renin-angiotensin-aldosterone system in diabetes and its vascular complications. Am J Hypertens. 2004;17:16S–20S
  5. Jacob S, Rett K, Henriksen EJ. Antihypertensive therapy and insulin sensitivity: do we have to redefine the role of beta-blocking agents?. Am J Hypertens. 1998;11:1258–1265
  6. Scheen AJ. CAPPP trial (Captopril Prevention Project). Lancet. 1999;353:1793–1794
  7. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais GHeart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342:145–153
  8. ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA. 2000;283:1967–1975
  9. Lindholm LH, Ibsen H, Borch-Johnsen K, Olsen MH, Wachtell K, Dahlöf B, et al. Risk of new-onset diabetes in the Losartan Intervention for Endpoint Reduction in Hypertension study. J Hypertens. 2002;20:1879–1886
  10. Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens. 2003;21:875–886
  11. Kjeldsen SE, Julius S, Mancia G, McInnes GT, Hua T, Weber MA, et al. Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial. J Hypertens. 2006;24:1405–1412
  12. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet. 2007;369:201–207
  13. Scheen AJ. Renin-angiotensin system inhibition prevents type 2 diabetes mellitus (Part 1. A meta-analysis of randomised clinical trials). Diabetes Metab. 2004;30:487–496
  14. Bosch J, Yusuf S, Gerstein HC, Pogue J, Sheridan P, Dagenais G, et al. Effect of ramipril on the incidence of diabetes. N Engl J Med. 2006;355:1551–1562
  15. Califf RM, Boolell M, Haffner SM, Bethel MA, McMurray J, Duggal A, et al. Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial. Am Heart J. 2008;156:623–632
  16. Scheen AJ. Renin-angiotensin system inhibition prevents type 2 diabetes mellitus (Part 2. Overview of physiological and biochemical mechanisms). Diabetes Metab. 2004;30:498–505
  17. Leiter LA, Lewanczuk RZ. Of the renin-angiotensin system and reactive oxygen species: Type 2 diabetes and angiotensin II inhibition. Am J Hypertens. 2005;18:121–128
  18. Erbe DV, Gartrell K, Zhang YL, Suri V, Kirincich SJ, Will S, et al. Molecular activation of PPARg by angiotensin II type 1-receptor antagonists. Vascul Pharmacol. 2006;45:154–162
  19. Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, Copland I, et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet. 2008;372:1174–1183
  20. Tikellis C, Wookey PJ, Candido R, Andrikopoulos S, Thomas MC, Cooper ME. Improved islet morphology after blockade of the renin- angiotensin system in the ZDF rat. Diabetes. 2004;53:989–997
  21. Sjølie AK, Klein R, Porta M, Orchard T, Fuller J, Parving HH, et al. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial. Lancet. 2008;372:1385–1393
  22. Patel A, MacMahon S, Chalmers J, Neal B, Woodward M, Billot L, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007;370:829–840
  23. Bosch J, Lonn E, Pogue J, Arnold JM, Dagenais GR, Yusuf S. Long-term effects of ramipril on cardiovascular events and on diabetes: results of the HOPE study extension. Circulation. 2005;112:1339–1346
  24. Daly CA, Fox KM, Remme WJ, Bertrand ME, Ferrari R, Simoons ML. The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy. Eur Heart J. 2005;26:1369–1378
  25. Carr AA, Kowey PR, Devereux RB, Brenner BM, Dahlof B, Ibsen H, et al. Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies. Am J Cardiol. 2005;96:1530–1536
  26. Didangelos TP, Arsos GA, Karamitsos DT, Athyros VG, Georga SD, Karatzas ND. Effect of quinapril or losartan alone and in combination on left ventricular systolic and diastolic functions in asymptomatic patients with diabetic autonomic neuropathy. J Diabetes Complications. 2006;20:1–7
  27. Kawasaki D, Kosugi K, Waki H, Yamamoto K, Tsujino T, Masuyama T. Role of activated renin-angiotensin system in myocardial fibrosis and left ventricular diastolic dysfunction in diabetic patients—reversal by chronic angiotensin II type 1A receptor blockade. Circ J. 2007;71:524–529
  28. Tropeano AI, Boutouyrie P, Pannier B, Joannides R, Balkestein E, Katsahian S, et al. Brachial pressure-independent reduction in carotid stiffness after long-term angiotensin-converting enzyme inhibition in diabetic hypertensives. Hypertension. 2006;48:80–86
  29. Savoia C, Touyz RM, Endemann DH, Pu Q, Ko EA, De Ciuceis C, et al. Angiotensin receptor blocker added to previous antihypertensive agents on arteries of diabetic hypertensive patients. Hypertension. 2006;48:271–277
  30. Savoia C, Touyz RM, Volpe M, Schiffrin EL. Angiotensin type 2 receptor in resistance arteries of type 2 diabetic hypertensive patients. Hypertension. 2007;49:341–346
  31. Schiffrin EL. Remodeling of resistance arteries in essential hypertension and effects of antihypertensive treatment. Am J Hypertens. 2004;17:1192–1200
  32. Karalliedde J, Smith A, DeAngelis L, Mirenda V, Kandra A, Botha J, et al. Valsartan improves arterial stiffness in type 2 diabetes independently of blood pressure lowering. Hypertension. 2008;51:1617–1623
  33. Maahs DM, Snell-Bergeon JK, Kinney GL, Wadwa RP, Garg S, Ogden LG, et al. ACE-I/ARB treatment in type 1 diabetes patients with albuminuria is associated with lower odds of progression of coronary artery calcification. J Diabetes Complications. 2007;21:273–279
  34. Willemsen JM, Westerink JW, Dallinga-Thie GM, van Zonneveld AJ, Gaillard CA, Rabelink TJ, et al. Angiotensin II type 1 receptor blockade improves hyperglycemia-induced endothelial dysfunction and reduces proinflammatory cytokine release from leukocytes. J Cardiovasc Pharmacol. 2007;49:6–12
  35. Serebruany VL, Pokov AN, Malinin AI, O'Connor C, Bhatt DL, Tanguay JF, et al. Valsartan inhibits platelet activity at different doses in mild to moderate hypertensives: Valsartan Inhibits Platelets (VIP) trial. Am Heart J. 2006;151:92–99

PII: S0002-9149(09)01050-9

doi: 10.1016/j.amjcard.2009.05.015

American Journal of Cardiology
Volume 104, Issue 6 , Pages 835-839 , 15 September 2009

Article Tools

* Image Usage & Resolution